Global Vaccine Contract Manufacturing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In June 2023, FUJIFILM Corporation announced the opening of its commercial office in Tokyo. This facility is designed to enhance sales and customer support services for contract development and manufacturing of biologics and advanced therapies, specifically targeting pharmaceutical and biotechnology companies in Asia.

• In December 2023, Ajinomoto Co., Inc. has recently acquired All Forge Biologics Holdings, LLC shares. The facility was aimed to accelerate production capability for manufacturing and development of biologics. This expansion is expected to foster growth and innovation in Japan.

By Vaccine Type, the market includes categories such as Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, and mRNA Vaccines. Each type has its unique production process and requirements. The inactivated and live attenuated vaccines continue to dominate due to their established use in immunization programs worldwide. However, mRNA vaccines have emerged as a transformative technology, particularly highlighted by the rapid development and deployment of COVID-19 vaccines, contributing to their growing share in the market.

The Workflow segment highlights different phases in the manufacturing process, including Upstream Processing, Downstream Processing, and Fill and Finish. Upstream processing involves the cultivation and preparation of cells or microorganisms, which is essential for vaccine production. Downstream processing focuses on the purification and separation of the desired product from other cellular components. Fill and finish is the final step, where the vaccine is packaged and prepared for distribution. Each phase plays a vital role in ensuring product quality and regulatory compliance, impacting the overall efficiency of the manufacturing process.

By Type, the market can be divided into Contract Development and Manufacturing Organizations (CDMOs) and Contract Manufacturing Organizations (CMOs). CDMOs provide comprehensive services, including research, development, and manufacturing, supporting companies from initial formulation to large-scale production. CMOs primarily focus on manufacturing services, aiding in the production of vaccines at scale. Both types are essential for vaccine developers looking to outsource production to optimize costs and speed up the time-to-market for new vaccines.

The End Use segmentation includes Pharmaceutical Companies, Government Agencies, and Non-profit Organizations. Pharmaceutical companies often engage contract manufacturers to scale up production of vaccines while managing R&D in-house. Government agencies and non-profit organizations collaborate with manufacturers to produce vaccines for public health programs, especially for global immunization campaigns and emergency responses to outbreaks. The involvement of various stakeholders in the vaccine supply chain highlights the market’s role in supporting public health infrastructure and rapid response capabilities.

Finally, by Geography, the market is analyzed across regions such as North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America and Europe lead in terms of market share, driven by strong healthcare infrastructure, established CDMO services, and significant investments in vaccine R&D. The Asia-Pacific region is witnessing robust growth due to cost advantages, growing healthcare needs, and increasing investments in biopharmaceutical infrastructure. Each region presents unique opportunities for market expansion, shaped by local regulatory environments, healthcare priorities, and economic conditions.

Global Vaccine Contract Manufacturing Segment Analysis

In this report, the Global Vaccine Contract Manufacturing Market has been segmented by Vaccine Type, Workflow, Type, End Use, and Geography.

Global Vaccine Contract Manufacturing Market, Segmentation by Vaccine Type

The Global Vaccine Contract Manufacturing Market has been segmented by Vaccine Type into Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines and DNA Vaccines.

Attenuated vaccines are developed by weakening the live virus or bacteria so that it cannot cause disease. These vaccines are known for their strong and long-lasting immunity with fewer doses. Examples include the MMR (measles, mumps, and rubella) vaccine and the oral polio vaccine. The contract manufacturing for attenuated vaccines involves complex processes that ensure the virus or bacteria remains viable yet non-virulent. This segment is critical due to the robust immunity it provides, although it requires careful handling and storage.

Inactivated vaccines, on the other hand, contain viruses or bacteria that have been killed. These vaccines, such as the hepatitis A vaccine and the flu shot, are safer as they cannot cause the disease they aim to prevent. The production of inactivated vaccines involves killing the pathogen with chemicals, heat, or radiation, ensuring the antigenicity is preserved. This segment is marked by its stability and safety, making it suitable for a wider range of populations, including those with compromised immune systems.

Subunit vaccines include only parts of the virus or bacteria, such as proteins or sugars, that can provoke an immune response. Examples are the HPV (human papillomavirus) and hepatitis B vaccines. These vaccines are produced using recombinant DNA technology, which can be efficiently scaled in contract manufacturing settings. The focus on subunit vaccines is growing due to their safety profile and targeted immune response, which can be enhanced using adjuvants.

Toxoid vaccines contain inactivated toxic compounds produced by bacteria, which are used to immunize against diseases caused by those toxins. Diphtheria and tetanus vaccines are prime examples. The manufacturing of toxoid vaccines involves detoxifying the bacterial toxins, a process that needs precision to ensure safety and efficacy. This segment is important for preventing bacterial diseases that are primarily toxin-mediated.

DNA vaccines represent a newer approach, where genetically engineered DNA is introduced into the body to produce an antigen, eliciting an immune response. These vaccines, still largely in the experimental or early deployment stages, hold promise for various infectious diseases and have the advantage of being stable and easy to produce. Contract manufacturing for DNA vaccines involves advanced biotechnological processes, including plasmid preparation and delivery system development.

Global Vaccine Contract Manufacturing Market, Segmentation by Workflow

The Global Vaccine Contract Manufacturing Market has been segmented by Workflow into Downstream and Upstream.

Upstream processes encompass all activities related to the initial stages of vaccine production, including the development and cultivation of the biological materials required for vaccine manufacturing. This phase involves the preparation of cell cultures, fermentation, and the expression of antigens. Upstream processes are critical as they set the foundation for the entire vaccine production pipeline, focusing on the quality and consistency of the biological materials used. Innovations in upstream technologies, such as single-use bioreactors and advanced cell culture techniques, are enhancing production efficiency and scalability, thereby meeting the increasing global demand for vaccines.

Downstream processes, on the other hand, refer to the purification and formulation stages of vaccine production. Once the biological materials are produced in the upstream phase, they must be purified and processed to ensure safety and efficacy. This includes steps such as filtration, chromatography, and viral inactivation. Downstream processes are crucial for removing impurities and stabilizing the vaccine product for storage and distribution. Technological advancements in downstream processing, including the use of automated systems and high-resolution analytical tools, are significantly improving the quality and yield of the final vaccine product. The complexity of downstream processes often requires specialized expertise and equipment, making it a significant segment within the vaccine contract manufacturing market.

The segmentation of the vaccine contract manufacturing market by workflow highlights the distinct and complementary roles of upstream and downstream processes. Companies involved in vaccine contract manufacturing often specialize in one of these areas or offer comprehensive services that cover both segments. This specialization allows them to provide targeted expertise and advanced technologies that are essential for efficient and cost-effective vaccine production. The demand for contract manufacturing services is driven by factors such as the increasing complexity of vaccine development, the need for rapid production in response to pandemics, and the rising number of biopharmaceutical companies outsourcing their manufacturing processes to focus on core competencies like research and development.

Global Vaccine Contract Manufacturing Market, Segmentation by Type

The Global Vaccine Contract Manufacturing Market has been segmented by Type into Viral, Bacterial, and Others.

The Viral segment is a major component, focusing on vaccines and therapies designed to prevent or treat viral infections such as influenza, hepatitis, COVID-19, and human papillomavirus (HPV). This segment has seen significant advancements, particularly with the development of mRNA-based vaccines and vector-based technologies, which have demonstrated high efficacy against emerging viral threats. The growing prevalence of viral diseases and robust global vaccination programs continue to drive this segment's growth.

The Bacterial segment addresses bacterial infections such as tuberculosis, meningitis, and pneumococcal diseases. Vaccines in this category often rely on conjugate or inactivated bacterial components to elicit a strong immune response. The demand for bacterial vaccines has risen due to increasing antibiotic resistance and the prioritization of preventive measures in global health initiatives. Innovations in adjuvant technologies have further enhanced the effectiveness of bacterial vaccines, making them a critical focus area.

The Others category includes vaccines and products targeting less common or specialized pathogens, including parasitic or fungal infections. This segment also covers emerging therapeutic applications, such as cancer immunotherapies and autoimmune condition management. While smaller in scale compared to viral and bacterial segments, the "Others" category represents a growing area of interest, driven by ongoing research and development efforts to address unmet medical needs.

Global Vaccine Contract Manufacturing Market, Segmentation by End Use

The Global Vaccine Contract Manufacturing Market has been segmented by End Use into Biopharmaceutical Companies and Research Academies & Government Institutes.

Biopharmaceutical Companies form a dominant segment, leveraging vaccine technologies, adjuvants, and therapeutic innovations to address global health challenges. These companies focus on the development, production, and commercialization of vaccines and related products to meet rising demand for effective preventive and therapeutic solutions. With significant investments in research and development, biopharmaceutical firms are at the forefront of innovation, pioneering breakthroughs in areas such as mRNA vaccines, recombinant technologies, and personalized medicine. Their role in scaling production and ensuring global distribution further cements their position as key players in the market.

Research Academies & Government Institutes represent another critical end-user segment, driving foundational research and policy-driven initiatives in vaccine and therapeutic development. These entities are pivotal in understanding disease mechanisms, evaluating vaccine efficacy, and addressing public health priorities. Government institutes often collaborate with private companies to accelerate the development of vaccines for infectious diseases and emerging health threats. Research academies contribute by fostering scientific discovery, clinical trials, and training the next generation of researchers in cutting-edge methodologies.

Both end-use segments play indispensable roles in shaping the future of healthcare. Biopharmaceutical companies ensure the practical application and commercialization of innovations, while research academies and government institutes provide the scientific and policy frameworks necessary to advance global health initiatives. Together, they form a synergistic ecosystem that drives progress in the field.

Global Vaccine Contract Manufacturing Market, Segmentation by Geography

In this report, the Global Vaccine Contract Manufacturing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Vaccine Contract Manufacturing Market Share (%), by Geographical Region, 2024

North America represents a significant portion of the global vaccine contract manufacturing market. The region's advanced healthcare infrastructure, robust research and development capabilities, and the presence of major pharmaceutical and biotechnology companies contribute to its leading position. Countries such as the United States and Canada are at the forefront, leveraging their technological advancements and regulatory support to facilitate vaccine production. The COVID-19 pandemic has further accelerated investments in vaccine manufacturing capacities within the region, highlighting its critical role in global vaccine supply chains.

Europe is another crucial region in the vaccine contract manufacturing market. The region boasts a well-established pharmaceutical industry and strong governmental support for healthcare innovations. Key countries such as Germany, the United Kingdom, and France are pivotal players, housing numerous contract manufacturing organizations (CMOs) and extensive R&D facilities. The European Medicines Agency (EMA) ensures stringent regulatory standards, which bolster the reliability and quality of vaccine manufacturing. Collaborative efforts among European nations and substantial funding for biopharmaceutical research underscore the region's importance in the global market.

The Asia Pacific region is experiencing rapid growth in the vaccine contract manufacturing market, driven by countries like China, India, Japan, and South Korea. These nations are increasingly becoming hubs for biopharmaceutical production due to their cost-effective manufacturing capabilities, skilled workforce, and favorable government policies. The region's growing population and rising healthcare needs further augment demand for vaccines. Investments in biotechnology infrastructure and strategic partnerships with global pharmaceutical companies enhance Asia Pacific's competitive edge, positioning it as a vital contributor to the global vaccine supply chain.

The Middle East and Africa region is gradually emerging in the vaccine contract manufacturing market. While traditionally reliant on imports, there is a growing focus on developing local manufacturing capabilities to ensure vaccine self-sufficiency. Countries such as South Africa, Saudi Arabia, and the United Arab Emirates are making strides in enhancing their pharmaceutical infrastructure. Regional collaborations and support from international organizations are pivotal in bolstering the vaccine manufacturing landscape. Despite challenges such as limited resources and regulatory hurdles, the region holds potential for significant growth in the coming years.

Latin America presents a growing market for vaccine contract manufacturing, with countries like Brazil, Mexico, and Argentina leading the charge. The region's expanding pharmaceutical sector, combined with increasing investments in healthcare, supports its development as a key player. Latin American governments are actively seeking to boost local production capacities to reduce dependency on imports and improve vaccine accessibility. Collaborative efforts with global pharmaceutical giants and regional initiatives aimed at enhancing R&D capabilities further drive the market's growth in this region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Vaccine Contract Manufacturing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers

• Growing Vaccine Demand Globally
• Technological Advancements in Manufacturing
• Increasing Government Initiatives

• Rise in Infectious Diseases: The global vaccine contract manufacturing market is experiencing substantial growth, driven by several critical factors. One of the most significant contributors to this expansion is the increasing incidence of infectious diseases worldwide. As new and re-emerging pathogens continue to pose a threat to public health, there is a heightened demand for vaccines. Contract manufacturing organizations (CMOs) are stepping in to meet this demand, providing essential services such as production, formulation, and packaging of vaccines. These organizations offer scalability, expertise, and cost-effectiveness, making them indispensable partners for pharmaceutical companies looking to accelerate vaccine development and distribution.

  Technological advancements in vaccine development are also propelling the market forward. Innovations in biotechnology and genetic engineering have led to the creation of more effective and diverse vaccines. CMOs are leveraging these advancements to enhance their manufacturing processes, ensuring higher efficiency and better quality control. This, in turn, has made it feasible to produce vaccines on a larger scale and at a faster pace, which is crucial in the face of outbreaks. The ability to rapidly respond to emerging infectious diseases with effective vaccines is a key driver of the growing reliance on contract manufacturing in the vaccine sector.

  In addition to technological advancements, government initiatives and funding are playing a crucial role in the expansion of the vaccine contract manufacturing market. Governments around the world are investing heavily in vaccine research and development, recognizing the importance of preparedness against infectious diseases. This support often extends to CMOs, enabling them to expand their capacities and improve their technologies. Public-private partnerships are becoming more common, fostering an environment of collaboration that is essential for addressing global health challenges. As the threat of infectious diseases persists, the global vaccine contract manufacturing market is expected to continue its upward trajectory, bolstered by these concerted efforts and innovations.

Restraints

• High Production Costs
• Stringent Regulatory Requirements
• Limited Skilled Workforce

• Supply Chain Disruptions: These disruptions arise from various factors, including regulatory challenges, raw material shortages, and geopolitical tensions. Regulatory hurdles, such as stringent approval processes and changing compliance requirements across different regions, often delay the production and distribution of vaccines. Moreover, the reliance on a complex network of suppliers for raw materials and manufacturing components introduces vulnerabilities into the supply chain, making it susceptible to disruptions caused by natural disasters, transportation issues, or geopolitical conflicts.

  Raw material shortages pose another major challenge to vaccine contract manufacturing. Many vaccine components require specialized raw materials that may have limited availability or face production constraints. Fluctuations in the supply of these materials can disrupt manufacturing schedules and lead to delays in vaccine production. Additionally, geopolitical tensions and trade disputes can further exacerbate these shortages by restricting the flow of raw materials across borders. This not only impacts the timely delivery of vaccines but also increases production costs for manufacturers as they scramble to secure alternative sources for essential materials.

  In response to these challenges, vaccine contract manufacturers are increasingly adopting strategies to mitigate supply chain disruptions. This includes diversifying their supplier base to reduce dependency on single sources, investing in advanced inventory management systems to ensure adequate stock levels of critical materials, and enhancing collaboration with regulatory authorities to navigate complex approval processes more efficiently. Furthermore, the industry is exploring innovative technologies such as predictive analytics and blockchain to improve supply chain visibility and resilience. Despite these efforts, supply chain disruptions remain a persistent challenge for the vaccine contract manufacturing market, requiring ongoing adaptation and investment in risk management strategies.

Opportunities

• Expansion in Emerging Markets
• Collaborations and Partnerships
• Investment in R&D

• Development of Novel Vaccines: The global vaccine contract manufacturing market has witnessed substantial growth in recent years, driven by the increasing demand for novel vaccines across various therapeutic areas. Contract manufacturing organizations (CMOs) play a crucial role in the development and production of these vaccines, offering expertise, infrastructure, and scalability to meet the growing needs of vaccine developers. With advancements in biotechnology and immunology, there has been a surge in the development of innovative vaccines targeting a wide range of infectious diseases, chronic conditions, and cancers. These novel vaccines often require specialized manufacturing processes and facilities, which CMOs are well-equipped to provide.

  One significant trend in the development of novel vaccines is the focus on personalized medicine and targeted immunotherapies. Traditional vaccines have been effective in preventing infectious diseases on a population level, but there is increasing interest in vaccines tailored to individual genetic profiles and disease characteristics. This personalized approach holds promise for more effective and safer vaccines, particularly in the treatment of cancer and autoimmune disorders. CMOs are collaborating with biopharmaceutical companies and research institutions to develop and manufacture these next-generation vaccines, leveraging their expertise in cell culture, gene therapy, and formulation technologies.

  The emergence of infectious diseases such as Ebola, Zika, and dengue fever has underscored the need for rapid vaccine development and production capabilities. In response to global health threats, governments, NGOs, and private companies are investing in the development of vaccines against emerging pathogens. CMOs play a vital role in this endeavor, providing flexible and scalable manufacturing solutions to accelerate the production timeline and ensure widespread access to vaccines. By leveraging their expertise in process optimization and regulatory compliance, CMOs enable vaccine developers to bring new products to market quickly and efficiently, addressing critical public health needs on a global scale.

Key players in Global Vaccine Contract Manufacturing Market include:

• Catalent, Inc
• Lonza Group AG
• Samsung Biologics
• Emergent BioSolutions Inc
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific Inc
• Wuxi Biologics
• Cobra Biologics
• AGC Biologics
• Recipharm AB

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis